CIP
FPRX

Convergence Investment Partners’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Convergence Investment Partners’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-20,480
Closed -$847K – 407
2016
Q2 		$847K Buy
+20,480
New +$891K 0.12% 255

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Convergence Investment Partners's FPRX Position: Q3 2016 in Review

Convergence Investment Partners sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2016, closing a stake of 20,480 shares — an estimated $847K sold.

Convergence Investment Partners first reported a position in FPRX in Q2 2016 and held it in 1 quarter. The position peaked at $847K in Q2 2016. 176 funds tracked by Wall St. Rank hold FPRX as of Q3 2016.

  • Convergence Investment Partners reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Convergence Investment Partners sold 20,480 Five Prime Therapeutics, Inc. shares in Q3 2016, an estimated $847K.
  • Convergence Investment Partners first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 1 quarter.
  • Convergence Investment Partners's Five Prime Therapeutics, Inc. position peaked at $847K in Q2 2016.
  • 176 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2016.

Based on Convergence Investment Partners's 13F filing for Q3 2016, filed 10 Nov 2016.